President Donald Trump has placed special emphasis on reversing initiatives directly associated with his predecessor, but one important Obama era executive order for the biopharma sector has – so far at least – remained in effect: the initiative to combat antibiotic resistance.
In particular, the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) is wrapping up work on a report on incentives...





